Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | HTR1D | P28221 | 7/20 | 0.37 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | HTR1B | P28222 | 5/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8096925 | 0.90 | HTR1D (0.37) | HTR1DHTR1AHTR1BROCK2CCR2 | |
| SCHEMBL8096594 | 0.90 | HTR1D (0.40) | HTR1DHTR1AHTR1BROCK2CCR2 | |
| SCHEMBL4242109 | 0.90 | CHRM4 (0.40) | HTR1DHTR1AHTR1BROCK2CCR2 | |
| SCHEMBL8096424 | 0.83 | CHRM4 (0.41) | HTR1DHTR1AHTR1B | |
| SCHEMBL8096419 | 0.83 | CHRM4 (0.41) | HTR1DHTR1AHTR1B | |
| SCHEMBL8094478 | 0.82 | MEN1 (0.40) | HTR1DMEN1KMT2A | |
| SCHEMBL8100440 | 0.82 | PDE4B (0.35) | HTR1DMEN1KMT2ADHODH | |
| SCHEMBL4242852 | 0.82 | PDE4B (0.36) | HTR1D | |
| SCHEMBL8094627 | 0.80 | CHEK2 (0.44) | HTR1DHTR1AHTR1BROCK2CCR2 | |
| SCHEMBL4249271 | 0.80 | SMN1; SMN2 (0.49) | GRIN1GRIN2BHTR1DHTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | GRIN1 109/4885GRIN2B 80/4885HTR1D 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.